Image
Engaging the Patient™

What’s New in Systemic Lupus Erythematosus?

Unlocking Novel Paths to Patient Care

Meeting Slides

Suggested Readings

European League Against Rheumatism (EULAR) 2020 Annual Meeting Abstracts.

June 3-6, 2020. Virtual.

American College of Rheumatology (ACR) Annual Meeting Abstracts.

November 5-9, 2020. Virtual.

Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.

van Vollenhoven RF, et al. Ann Rheum Dis. 2014;73(6):958-967.

Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.

Furie RA, et al. Lancet Rheumatol. 2019;1(4):e208-e219.

Trial of anifrolumab in active systemic lupus erythematosus.

Morand EF, et al. N Engl J Med. 2020;382(3):211-221.

Anifrolumab, an anti–interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus.

Furie R, et al. Arthritis Rheumatol. 2017;69(2):376-386.

A phase 3, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.

Furie R, et al. Arthritis Rheum. 2011;63(12):3918-3930.

Two-year, randomized, controlled trial of belimumab in lupus nephritis.

Furie RA, et al. N Engl J Med. 2020;383(12):1117-1128.

Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab.

Morand EF, et al. Ann Rheum Dis. 2018;77(5):706-713.

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Navarra SV, et al. Lancet. 2011;377(9767):721-731.

AURORA phase 3 study demonstrates voclosporin statistical superiority over standard of care in lupus nephritis.

Arriens C, et al. Ann Rheum Dis. 2020;79(suppl 1):172-173.

B-cell depletion and response in a randomized, controlled trial of obinutuzumab for proliferative lupus nephritis.

Furie R, et al. Lupus Sci Med. 2020;7(suppl 1):A27-A28.

Comprehensive efficacy of anifrolumab across organ domains in patients with active SLE: pooled data from 2 phase 3 trials.

Morand E, et al. Arthritis Rheumatol. 2020;72(suppl 10).

Flare reduction and oral corticosteroid taper in patients with active SLE treated with anifrolumab in 2 phase 3 trials.

Furie R, et al. Arthritis Rheumatol. 2020;72(suppl 10).

Interactive Presentation

Immunopathogenesis of SLE


Relevant Resources

Clinical Updates in Systemic Lupus Erythematosus

Improved Diagnostic and Management Strategies

Persistent and Breakthrough Pain

Balancing the Benefits and Risk of Opioid-Based Therapy

Improving the Care of Patients With Chronic Pain

Individualized Assessment and Mechanism-Based Multimodal Treatment

Caring For Patients With Chronic Pain

Responsible Opioid Prescribing to Achieve Individualized Functional Goals

Advances in Immunosupressive Therapy for Solid Organ Transplantation

Long-Term Management Strategies to Improve Patient Outcomes

Acute Management of Migraine Attacks

Overcoming Pain and Gastrointestinal Distress to Improve Patient Outcomes

Opioid-Induced Constipation

Proactive Diagnosis and Targeted Management

Intrathecal Drug Delivery for Chronic Pain

Selecting Patients and Optimizing Long-Term Outcomes

Clinical Updates on the Management of Gout

Evidence-Based Strategies for Improved Patient Outcomes

Opioid-Induced Constipation

Proactive Diagnosis and Targeted Management

Chronic Obstructive Pulmonary Disease, Asthma, or Both

Differential Diagnosis and Comprehensive Management Strategies

Improving Outcomes in Chronic Obstructive Pulmonary Disease

Optimizing Maintenance Therapy Across Healthcare Settings

Managing Gout in Primary Care

Evolving Strategies for Diagnosis and Long-Term Management

Clinical Issues in Chronic Pain

Consensus and Controversies for Responsible Opioid Prescribing

Noninsulin Approaches to Managing Type 2 Diabetes

Best Practices in Combination Therapy

Intrathecal Drug Delivery for Chronic Pain

The Role of Nurses in Optimizing Long-term Outcomes

Hitting the Target in Type 2 Diabetes

Evolving Approaches to Insulin Based Therapy

Intrathecal Drug Therapy for Chronic Pain

Evolving Best-Practice Strategies to Maximize Efficacy and Safety

Improving Outcomes in Rheumatoid Arthritis

Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms

Clearing the Air

Improving Outcomes for Patients with COPD

Clinical Updates in Type 2 Diabetes

New Strategies for Insulin Replacement Therapy

How Low Do You Go?

Clinical Updates in LDL-C Management

Incretin-Based Therapies For Type 2 Diabetes

Improving Comprehensive Patient Care

Improving Outcomes in Non–24-Hour Sleep-Wake Disorder

Identifying Patients and Tailoring Therapy

Comprehensive Management of Chronic Obstructive Pulmonary Disease

Collaborative Approaches to Guideline-Concordant Patient Care

Clinical Updates in the Management of Severe Asthma

New Strategies for Individualizing Long-term Care

Comprehensive Chronic Pain Management

A Focus on Patients With Opioid-Induced Constipation

Clinical Issues in Bipolar Depression

Consensus and Controversies Across the Spectrum of Patient Presentations

Clinical Updates in Rheumatoid Arthritis

Evolving Treatment Algorithms and Expert Perspectives on Biosimilars

Best Practices in Intrathecal Therapy for Chronic Pain

Patient Selection, Treatment Initiation, and Ongoing Monitoring

Going Deeper on Atopic Dermatitis

Pathophysiology to the Management of Moderate-to-Severe Disease

Overcoming Challenges in Cancer Pain Management

Engaging With Patients About Opioid-Induced Constipation

Caring for Patients with Severe Asthma

Evolving Best Practices to Optimize Outcomes

Looking Beneath The Surface In Atopic Dermatitis

Targeting Immune Dysregulation and Delivering Comprehensive Care

Can You Spot Axial Spondyloarthritis?

The PCP’s Role in Timely Recognition and Referral

Evolving Treatment Paradigms For Rheumatoid Arthritis

Translating Comprehensive Patient Evaluations Into Personalized Therapy

Clinical Updates in Rheumatoid Arthritis

New Perspectives on Targeting Remission and Individualizing Therapy

A Better Look at Rheumatoid Arthritis

Using Imaging to Improve Patient Outcomes

Clinical Issues in Chronic Pain

Debates and Discussions About Therapeutically Targeting Nerve Growth Factor Signaling

Clinical Issues in Rheumatoid Arthritis

Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs

Advancing the Care of Severe Asthma

Differential Diagnosis, Multidisciplinary Management, and Patient Engagement

Updates in HCV Screening and Treatment

Key Issues Impacting OB/GYN Practice

Comprehensive Relief from Cancer Pain

Expanding the Conversation on Opioid-Induced Constipation

Pathways to Better Outcomes in Systemic Lupus Erythematosus

Translating Pathophysiology into Targeted Treatments

The Big Picture of IBD

An Interactive Experience Highlighting Recent Clinical Advances

Evolving Models of HIV Care

Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice

Clinical Issues in Rheumatoid Arthritis

Debates & Discussions on the Evolving Role of JAK Inhibitors

Managing Opioid-Induced Constipation

Translating Guidelines Into Patient Care

Clearing the Air in Severe Asthma Management

Improving Patient Outcomes Through Shared Clinical Decision Making

GLP-1 Receptors Agonists in Type 2 Diabetes

Mechanistic Insights and Evolving Treatment Options

Clinical Issues in Rheumatoid Arthritis

The Evolving Role of JAK Inhibitors

JAKi in RA Practice

Unpacking the Evidence for Their Use Today and Tomorrow

Airing It Out

A Case-Based Conversation on Managing Asthma and Chronic Rhinosinusitis With Nasal Polyposis

COPD in Managed Care

The Clinical and Utilization Benefits of Exacerbation Prevention

Assimilating the Evidence in T2DM

Cardiovascular and Renal Outcomes With SGLT2 Inhibitors

Demystifying New Evidence for COPD Management

Best Practices for Primary Care

Finding Relief in Osteoarthritis

New Paths to Chronic Pain Management

The Changing Landscape of HIV Prevention

What the Pharmacist Needs to Know about PrEP